Ixabepilone
- TRADE NAME: Ixempra (Bristol-Myers Squibb)
- INDICATIONS: Breast cancer (advanced or metastatic)
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Epithilone
- HALF-LIFE: 52 hours
Amprenavir, Atazanavir, Carbamazepine, Clarithromycin, Conivaptan, Darunavir, Dasatinib, Deferasirox, Delavirdine, Dexamethasone, Efavirenz, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Voriconazole
PREGNANCY CATEGORY: D
Often prescribed along with capecitabine. Patients with diabetes may be at increased risk of severe neuropathy.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of ixabepilone in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/03/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
